Ifex

ifosfamide · IFOSFAMIDE 1 g/20mL · Injection, Powder, For Solution · Intravenous · Baxter Healthcare Corporation

NDC 00338-3991-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$36.74

Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 GM

$27.613

HCPCS J9208 · Jul 1, 2026 quarter · typically ASP + 6%

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Baxter Deutschland GmbHGermany
api manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA019763
TE code: AP
Approval date: Dec 30, 1988
Patents / exclusivity: None on file

Shortage history

In shortage now — IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)Jun 12, 2026
Requirements related to complying with good manufacturing practices
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months
In shortage now — IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)Jun 12, 2026
Requirements related to complying with good manufacturing practices
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months
In shortage now — Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)Jun 12, 2026
Requirements related to complying with good manufacturing practices
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months
In shortage now — Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)Jun 12, 2026
Requirements related to complying with good manufacturing practices
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of ifosfamide (Injection, Powder, For Solution)

Labeler	Strength	First seen	Last seen
Baxter Healthcare Company	IFOSFAMIDE 1 g/20mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Company	IFOSFAMIDE 3 g/60mL	Jul 15, 2026	Sep 3, 2026
Baxter Healthcare Corporation	IFOSFAMIDE 1 g/20mL	Jul 15, 2026	Sep 2, 2026
Baxter Healthcare Corporation	IFOSFAMIDE 3 g/60mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ifex — NDC 00338-3991-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00338399101.

Free to cite with attribution — see how the data is put together.